On June 3, the Ministry of Health published the latest Update to the First 2020 Edition of the drug book of the National Compendium of Health Supplies in the Official Gazette, which is already in force. The Update contains the list of drugs approved for public health institutions handling health issues affecting the Mexican population. The list of active ingredients includes oncological drugs such as ixazomib. In other news, the Ministry of Economy concluded negotiations for multiple protocols under the Treaty with the United States and Canada (USMCA), taking a further step towards implementation scheduled to begin on July 1.
The updated list includes drugs such as risedronate, cholecalciferol, and azithromycin. It also modifies certain provisions on oncological drugs such as alectinib, pembrolizumab; ; risedronic acid for the treatment of postmenopausal osteoporosis; antiparasitic and antirheumatic drugs such as hydroxychloroquine; and benralizumab for the treatment of severe asthma as well as mepolizumab for severe refractory eosinophilic asthma.
The Ministry of Economy (SE) also reported on the conclusion of technical negotiations foreseen in Article 5.16 of the United States-Mexico-Canada Treaty (USMCA), bringing the treaty closer to its entry into force on July 1. As a result of the process, each party undertakes to adopt or maintain uniform rules for the interpretation, application, and administration of the chapters on rules of origin; origin procedures; and customs administration and trade facilities.